Western drugmakers can't afford to ignore India, which is expected to be the eighth-largest market for drugs within three years, despite suffering a landmark patent setback. "Companies will definitely get cautious, and it definitely means a change in their business model, but I don't think they will pull out," IMS Health's Amit Backliwal said. Experts said makers of brand-name drugs need to develop innovative business models for the country, including collaborating with domestic companies to create less-expensive products, some analysts say.

Full Story:

Related Summaries